Protagonist Therapeutics (MEX:PTGX) Other Current Liabilities: MXN76 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PTGX Protagonist Therapeutics Inc MEX:PTGX
47 GF Score
Price MXN1,565.33
GF Value MXN793.86
! 8 Warning Signs
View Full Analysis

What is Protagonist Therapeutics Other Current Liabilities?

Protagonist Therapeutics MEX:PTGX 47 Other Current Liabilities is MXN76 Mil as of Mar. 2026. GuruFocus rates MEX:PTGX with a GF Score™ of 47/100 and a GF Value™ of MXN793.86. The stock has 8 warning signs investors should review.

Protagonist Therapeutics's other current liabilities for the quarter that ended in Mar. 2026 was MXN76 Mil.

Protagonist Therapeutics's quarterly other current liabilities increased from Sep. 2025 (MXN138 Mil) to Dec. 2025 (MXN230 Mil) but then declined from Dec. 2025 (MXN230 Mil) to Mar. 2026 (MXN76 Mil).

Protagonist Therapeutics's annual other current liabilities increased from Dec. 2023 (MXN115 Mil) to Dec. 2024 (MXN231 Mil) but then declined from Dec. 2024 (MXN231 Mil) to Dec. 2025 (MXN230 Mil).

Protagonist Therapeutics Other Current Liabilities Related Terms

Protagonist Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Protagonist Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Protagonist Therapeutics Other Current Liabilities Chart

Protagonist Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 146.16 96.84 115.19 231.04 229.83

Protagonist Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.31 94.26 138.11 229.83 76.35
MEX:PTGX
47GF Score
Protagonist Therapeutics Inc MEX:PTGX
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Protagonist Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of MXN76 Mil mean?
Protagonist Therapeutics (MEX:PTGX) has a Other Current Liabilities of MXN76 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Protagonist Therapeutics.
Is Protagonist Therapeutics' Other Current Liabilities too high?
Protagonist Therapeutics' current Other Current Liabilities is MXN76 Mil. Overall, Protagonist Therapeutics has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Protagonist Therapeutics' Other Current Liabilities compare to CRNX and SYRE?
Protagonist Therapeutics' Other Current Liabilities of MXN76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Protagonist Therapeutics. Protagonist Therapeutics's current Other Current Liabilities is MXN76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protagonist Therapeutics stock overvalued right now?
Protagonist Therapeutics (MEX:PTGX) has a current Other Current Liabilities of MXN76 Mil. The stock's GF Value™ is MXN793.86, compared to a current price of MXN1,565.33 — trading 97.2% above its estimated fair value. The current Other Current Liabilities is MXN76 Mil. Protagonist Therapeutics' overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Protagonist Therapeutics (MEX:PTGX), the current Other Current Liabilities is MXN76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Protagonist Therapeutics (MEX:PTGX) Overvalued in 2026?

Based on GuruFocus' analysis, Protagonist Therapeutics stock appears to be overvalued. The current stock price of MXN1,565.33 is trading 97.2% above its estimated GF Value™ of MXN793.86.

Key valuation signals for MEX:PTGX:

  • Other Current Liabilities: MXN76 Mil
  • GF Value™: MXN793.86 vs. price of MXN1,565.33 (97.2% above fair value)
  • GF Score™: 47/100 with 8 warning signs

No single metric tells the full story. See the MEX:PTGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Protagonist Therapeutics Business Description

Other Exchanges PTGX:USA
Address 7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
47GF Score

Get the complete analysis for MEX:PTGX

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,565.33
Price
MXN793.86
GF Value